Promega SABiosciences Agreement Enables the Most Sensitive Tools for Pathway Analysis
News Aug 18, 2009
Promega and SABiosciences will combine their offerings to provide sensitive tools for interrogating specific cellular pathways via transcription factor reporters.
Under the new agreement Promega recombinant firefly luciferase luc2 gene and a humanized Renilla luciferase (hRluc) gene- the ‘dual luciferases’- will serve as one key reporter system for SABiosciences pathway reporter assays under the Cignal™ moniker.
Cignal transcription reporters from SABiosciences offer the widest selection of pathway activity assays, featuring more than 40 pathway reporters available in both DNA construct and viral particle formats.
“We are pleased to include Promega’s recombinant firefly and humanized Renilla luciferases as reporters in our product lines. They provide the necessary levels of sensitivity for studying the effects of drugs or genetic perturbations on many interesting and biologically relevant cell types.” said Dave Martz, VP of Sales and Marketing at SABiosciences.
The Cignal products with Promega luciferase technology are currently available in tube and plate formats for multiple pathways of biological interest.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.